CD4 and neoplasm: In the ICI-treated PyMT tumor-bearing hCD4-KI mice, the 64Cu-CD4-Nb1 uptake was significantly higher (0.44 ± 0.04 %ID/ml) than in the ICI-treated PyMT tumor-bearing WT mice.